PsA Screening Questionnaire for Psoriatic Arthritis
Trial Summary
What is the purpose of this trial?
The overarching goal of this study is to develop a direct-to-patient screening approach that will improve early Psoriatic Arthritis (PsA) detection in patients with psoriasis. Previously developed screening questionnaires were intended for use in the setting of a doctor's office to assist providers with referral decisions. However, these screening questionnaires are infrequently used in routine practice because of limitations with time and resources. The study will aim to develop a practical screening strategy that does not require involvement from dermatologists (or other non-rheumatology providers) and can systematically reach a broad range of psoriasis patients, including patients not attending dermatology clinics. The researchers hypothesize that disseminating questionnaires directly to patients outside of a clinic setting (direct-to-patient approach) will educate patients about their PsA risk and improve early PsA diagnoses.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the PsA Screening Questionnaire for Psoriatic Arthritis treatment?
The Psoriasis Epidemiology Screening Tool (PEST) has shown a high sensitivity of 0.94, meaning it is effective at correctly identifying those with psoriatic arthritis, and a specificity of 0.78, indicating it can also correctly identify those without the condition. The Toronto Psoriatic Arthritis Screen (ToPAS) has been validated and refined to improve its ability to distinguish between those with and without psoriatic arthritis.12345
Is the PsA Screening Questionnaire safe for humans?
Is the PsA Screening Questionnaire for Psoriatic Arthritis a promising treatment?
Research Team
Jessica Walsh, M.D.
Principal Investigator
University of Utah
Eligibility Criteria
This trial is for adults over 18 with a diagnosis of psoriasis who haven't been diagnosed with Psoriatic Arthritis. Participants should live close to the study site and have not started any treatment for Psoriatic Arthritis.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive a PsA screening questionnaire and are either instructed to talk with their doctor about a rheumatology referral or given direct access to schedule a rheumatologic evaluation.
Follow-up
Participants are monitored for new PsA diagnoses and rheumatologic evaluations, as well as disease severity and activity.
Treatment Details
Interventions
- Direct to patient PsA Screening Questionnaire (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jessica Walsh
Lead Sponsor